Fundraising Fox

/Companies

Conkwest

NASDAQ: IBRXUnicorn · $2B

Cardiff-By-The-Sea, US · Delaware corporation

Find your way into Conkwest

Sign up to see every warm intro you have to Conkwest

Paths you didn't know you had: your email and LinkedIn already hold routes to the Conkwest team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with Google Already have an account? Log in

ImmunityBio develops and commercializes immunotherapy products and candidates, including ANKTIVA, an approved treatment for bladder and lung cancer, along with cell therapies and vaccine platforms designed to activate immune response against cancer and infectious diseases.

Founders & leadership

RG

Richard GombergExecutive

RA

Richard AdcockDirector, CEO and President

BJ

Barry J. Simon

Barry J. SimonDirector and Chief Corporate Affairs Officer

SG

Steven GorlinNamed on SEC filing

HG

Hans G. KlingemannNamed on SEC filing

Board

HJ

Henry JiBoard director

JT

John ThomasBoard director

PS

Patrick Soon-ShiongBoard director

RK

Richard KusserowBoard director

RR

Robert RosenBoard director

JP

John PottsBoard director

Reported raises · per SEC filings

Form D private placements

$639.6M disclosed across 7 of 9 rounds · 1900–2023

▶$470MraisedSep 2023 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Patrick Soon-ShiongExecutive Officer, Director
Cheryl CohenDirector
Linda MaxwellDirector
Michael BlaszykDirector
Wesley ClarkDirector
Richard AdcockExecutive Officer, Director
Barry SimonDirector
John BrennanDirector
David SachsExecutive Officer
Christobel SeleckyDirector

Offering amount: $470M
Amount sold: $470M
Sales commissions: $1M
First sale: Sep 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10.7MraisedJul 2022 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Michael BlaszykDirector
Barry SimonDirector
Christobel SeleckyDirector
John BrennanDirector
Wesley ClarkDirector
Linda MaxwellDirector
Richard AdcockExecutive Officer, Director
Patrick Soon-ShiongExecutive Officer, Director
David SachsExecutive Officer
Cheryl CohenDirector

Offering amount: $10.7M
Amount sold: $10.7M
First sale: Jul 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$17MraisedAug 2015 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John T. Potts, Jr., M.D.Director
Henry Ji, Ph.D.Director
John C. Thomas, Jr.Director
Richard GombergExecutive Officer
Barry J. Simon, M.D.Executive Officer, Director
Steve GorlinDirector
Robert RosenDirector
Michael BlaszykDirector
Richard KusserowDirector
Patrick Soon-Shiong, M.D.Executive Officer, Director

Offering amount: $17M
Amount sold: $17M
First sale: Jul 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$78MraisedJul 2015 · 11 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Steve GorlinDirector
Patrick Soon-Shiong, M.D.Executive Officer, Director
Barry J. Simon, M.D.Executive Officer, Director
Henry Ji, Ph.D.Director
John T. Potts, Jr., M.D.Director
Hans Klingemann, M.D., Ph.D.Director
Richard GombergExecutive Officer
Richard KusserowDirector
John C. Thomas, Jr.Director
Robert RosenDirector

Offering amount: $78M
Amount sold: $78M
First sale: Jun 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$47.5MraisedJan 2015 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Henry JiDirector
Richard KusserowDirector
John ThomasDirector
Richard GombergExecutive Officer
Patrick Soon-ShiongDirector
Barry SimonExecutive Officer, Director
Steven GorlinDirector
Hans G. KlingemannDirector
Robert RosenDirector
John PottsDirector

Offering amount: $47.5M
Amount sold: $47.5M
First sale: Dec 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedDec 2014 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Steven GorlinDirector
Hans G. KlingemannDirector
John ThomasDirector
Barry SimonExecutive Officer, Director
Robert RosenDirector
Richard KusserowDirector
Patrick Soon-ShiongDirector
Richard GombergExecutive Officer
Henry JiDirector
John PottsDirector

Offering amount: $10M
Amount sold: $10M
First sale: Dec 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$6.5MraisedApr 2014 · 48 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Hans KlingemannDirector
Barry SimonExecutive Officer, Director

Offering amount: $9.6M
Amount sold: $6.5M
Minimum investment: $5K
Sales commissions: $518.7K
Placement agents: Palladium Capital Advisors, LLC
First sale: Apr 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$2Bvaluation at IPOJul 2015 · $25.00/share · 424B4

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Conkwest do?: ImmunityBio develops and commercializes immunotherapy products and candidates, including ANKTIVA, an approved treatment for bladder and lung cancer, along with cell therapies and vaccine platforms designed to activate immune response against cancer and infectious diseases.
How much funding has Conkwest raised?: Conkwest has disclosed $639.6M raised across 7 of its 9 known rounds.
Where is Conkwest headquartered?: Conkwest is headquartered in Cardiff-By-The-Sea, US.